Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (546)	1/16/1998 9:52:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1686

Harold: You sort of lost me. But.... what I meant was.... I believe that BGEN will be successful, and that some companies with competitive (non-CD40L-related) projects won't look too attractive. Rick

To: Harold Engstrom who wrote (546)	1/16/1998 10:01:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

The balance sheet is very robust. The Smith Barney analyt referred to cash as being $350MM, but the actual figure is $440MM. Receivables are up and long term debt is up slightly. I question the put option shown on the liability side of the ledger: does anyone know what this is? I am guessing that the European launch will ramp up similarly to the US launch. If that is so, avonex revenues should increase by roughly $15-20MM per quarter. Maybe V1 can criticize these questimates - what is your opinion Vector? Harold